Jubilant Pharma Limited, an integrated pharmaceutical company, manufactures and markets active pharmaceutical ingredients (APIs), dosage forms, radiopharmaceuticals, and allergy therapy products. It operates in Contract Development and Manufacturing Operations, Specialty Pharmaceuticals, and Generics segments. The company offers APIs in the therapeutic areas of the cardiovascular system (CVS), central nervous system (CNS), anti-infectives, anti-diabetic, etc.; and solid dosage formulations for CVS, CNS, GI, and anti-allergy therapeutic categories. It also provides radiopharmaceuticals for diagnostic imaging of cardiology, oncology, lung, kidney, brain, and bone, as well as radiotherapy for thyroid and cancer; and allergy therapy products, such as allergenic extracts and mixes, and a line of specialized skin test devices, as well as venom extracts. In addition, the company offers contract manufacturing services of sterile injectables, ophthalmics, otics, sterile and non-sterile ointments, creams, and liquids; and insect venom products for the treatment of allergies to insect stings. Jubilant Pharma Limited offers its products in North America, Europe, Asia, and internationally. It has a strategic partnership with SOFIE Biosciences, Inc. to advance its theranostic pipeline, and support novel PET diagnostic manufacturing and distribution. The company was incorporated in 2005 and is based in Singapore. Jubilant Pharma Limited is a subsidiary of Jubilant Life Sciences Limited.